As of November 6, 2026, Traws Pharma, Inc. is a publicly traded company (Nasdaq: TRAW). The largest holder reporting an active stake on Schedule 13D is OrbiMed, at 11.9%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Sirenia Capital Management LP (9.9%), Ikarian Capital, LLC (9.5%), Chernett Jorey (6.8%) (Schedule 13D/A, May 5, 2026).
Is this your company?
About to sign with, pay or invest in Traws Pharma, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Traws Pharma, Inc. a real, registered company?
- Traws Pharma, Inc. files with the SEC under CIK 1130598 (its SEC filings).
- Its shares are listed under the ticker TRAW on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Newtown, Pennsylvania, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Traws Pharma, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Sirenia Capital Management LP (filed 2026-08-14).
Who are Traws Pharma, Inc.'s owners and officers?
Traws Pharma, Inc.: incorporated in Delaware; business address in Newtown, Pennsylvania; industry Pharmaceutical Preparations (Form D, 2026-11-05).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2026-11-05)
- : Executive Officer (Form D, 2026-11-05)
- : Director (Form D, 2026-11-05)
- : Director (Form D, 2026-11-05)
- : Director (Form D, 2026-11-05)
- : Director (Form D, 2026-11-05)
- : Director (Form D, 2026-11-05)
- : Director (Form D, 2026-11-05)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-08-14 | Sirenia Capital Management LP | 9.9% |
| Schedule 13G/A, 2026-08-14 | Ikarian Capital, LLC | 9.5% |
| Schedule 13G/A, 2026-08-14 | Squadron Master Fund LP | 0% |
| Schedule 13G/A, 2026-08-12 | Adage Capital Management, L.P. | 4.79% |
| Schedule 13G/A, 2026-05-15 | Squadron Master Fund LP | 6.4% |
| Schedule 13G/A, 2026-05-15 | Perceptive Advisors LLC | 6.1% |
| Schedule 13D/A, 2026-05-05 | Orbimed Advisors LLC | 11.9% |
| Schedule 13G/A, 2026-02-17 | Squadron Master Fund LP | 8.9% |
| Schedule 13G/A, 2026-02-17 | Ikarian Capital, LLC | 9.99% |
| Schedule 13G, 2026-02-12 | Adage Capital Management, L.P. | 9.14% |
| Schedule 13G/A, 2026-02-11 | Ayrton Capital LLC | 4.29% |
| Schedule 13G, 2026-01-16 | Chernett Jorey | 6.8% |
Questions about who owns Traws Pharma, Inc.
Who owns Traws Pharma, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Traws Pharma, Inc.: Orbimed Advisors LLC (11.9%, Schedule 13D/A, filed 2026-05-05), Sirenia Capital Management LP (9.9%, Schedule 13G, filed 2026-08-14), Ikarian Capital, LLC (9.5%, Schedule 13G/A, filed 2026-08-14), Chernett Jorey (6.8%, Schedule 13G, filed 2026-01-16) and Perceptive Advisors LLC (6.1%, Schedule 13G/A, filed 2026-05-15).
Who are the largest shareholders of Traws Pharma, Inc.?
By the share each holder's latest filing reports, the largest holders of Traws Pharma, Inc. on this page are Orbimed Advisors LLC (11.9%), Sirenia Capital Management LP (9.9%) and Ikarian Capital, LLC (9.5%).
When did Orbimed Advisors LLC buy into Traws Pharma, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Orbimed Advisors LLC on this page is the Schedule 13D/A, filed 2026-05-05, reporting 11.9%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Traws Pharma, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Traws Pharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Traws Pharma, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
21 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Traws Pharma, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- OrbiMed Capital GP VIII LLC, a 10% owner: 1,203,250 shares (7.8% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-04-28).
- OrbiMed, a 10% owner: 1,203,250 shares (7.8% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-04-28).
- , the chief executive and a director: 171,130 shares (1.1% of shares outstanding) (Form 4, 2025-12-16).
- , the chief operating officer and a director: 150,606 shares (0.98% of shares outstanding) (Form 4, 2025-12-16).
- , the chief science officer virology: 115,971 shares (0.75% of shares outstanding) (Form 4, 2025-12-16).
Shares outstanding: 15,368,277 as of 2026-08-12, from the company's latest SEC cover page.
How much has Traws Pharma, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2026-11-05 | $0 | $50M |
| Form D, 2024-04-16 | $14M | $14M |
Latest IPO step: Traws Pharma, Inc. filed to go public (S-1, 2026-10-26).
IPO filings: S-1, 2026-10-26, 424B4, 2024-12-31; ticker TRAW on Nasdaq Capital Market.
Keep reading
More on Traws Pharma, Inc. and the records around it.
Traws Pharma, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- Squadron Master Fund LP also filed stake reports on 14 other companies: Contineum Therapeutics, Inc. (Oct 2026), TCGX Acquisition Corp. II (Oct 2026), C4 Therapeutics, Inc. (Aug 2026)
- Chernett Jorey also filed stake reports on 16 other companies: CVRx, Inc. (Oct 2026), WW INTERNATIONAL, INC. (Aug 2026), Neuronetics, Inc. (Aug 2026)
- Sirenia Capital Management LP also filed stake reports on 19 other companies: Alto Neuroscience, Inc. (Aug 2026), ANAPTYSBIO, INC (Aug 2026), CYBIN INC. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/traws-pharma